PuSH - Publikationsserver des Helmholtz Zentrums München

Kronenberger, K. ; Diekmann, A.* ; Selmayr, M.* ; Strehl, J. ; Wahl, U. ; Lindhofer, H. ; Kraal, G.* ; Mocikat, R.

Impact of the lymphoma idiotype on in vivo tumor protection in a vaccination model based on targeting antigens to antigen-presenting cells.

Blood 99, 1327-1331 (2002)
DOI
Open Access Green möglich sobald Postprint bei der ZB eingereicht worden ist.
Trioma cell vaccination is a potent new immunologic approach for the therapy of malignant B-cell lymphoma. It is based on targeting tumor antigens to internalizing receptors on antigen-presenting cells (APCs). Tumor cells are fused to an APC-specific hybridoma, where they are converted to trioma cells that include potentially all lymphoma-derived antigens and that express the APC-binding arm. In this study, the mechanisms of, trioma-mediated tumor immunity in immunocompetent mice were dissected, and it was shown in this model system that humoral anti-idiotypic immunity is indeed detectable after idiotype-specific immunization but that it does not reflect the degree of tumor protection obtained in vivo. Immunization against the idiotype alone was not sufficient for efficient tumor rejection in vivo. Targeting tumor antigens to APCs Is only successful in terms of inducing tumor protection when designed as a polyvalent vaccination protocol.
Altmetric
Weitere Metriken?
Zusatzinfos bearbeiten [➜Einloggen]
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Korrespondenzautor
Schlagwörter BLOOD DENDRITIC CELLS; EFFICIENT PRESENTATION; BISPECIFIC ANTIBODIES; B-CELLS; CD64; MOLECULES; CHAIN; MICE
ISSN (print) / ISBN 0006-4971
e-ISSN 1528-0020
Zeitschrift Blood
Quellenangaben Band: 99, Heft: , Seiten: 1327-1331 Artikelnummer: , Supplement: ,
Verlag American Society of Hematology
Nichtpatentliteratur Publikationen
Begutachtungsstatus Peer reviewed